JPIAMR 14th Call Partner Search Tool

General Information

• Project title: Pre-clinical and clinical development of a novel, potent, broad spectrum antimicrobial agent
• Type: Project looking for partner
• Organisation: Fe Pharmaceuticals
• Country: United States (US)

Research area

• Scientific area(s) of the call:
  1. Optimisation of drug/plant protection agent combinations, alone or with adjunct therapies (including therapeutic vaccines)
  2. Design and implementation of new strategies (including optimisation of drug doses) for improved application, efficacy and delivery of single or combinations of antimicrobials
• One Health Setting:

  Human Health

• Type of studies/experimental approaches:

  preclinical and clinical studies in human and in all veterinary settings

• Keywords:

  pre-clinical; clinical; development; broad-spectrum AMRI

• Brief description of your expertise / expertise you are looking for:

  Fe Pharma management team have combined over 120 years experience in pre-IND, IND through clinical trial development and commercialization of a range of products, including anti- infectives.

• Brief description of your project / the project you would like to join:

  Fe Pharmaceuticals (www.fepharm.com) is reversing the effects of disrupted iron management in disease. Dysregulation of iron homeostasis can lead to or exacerbate a wide variety of diseases including infection, cancer, and inflammatory diseases. Fe Pharmaceuticals is developing DIBI, a non-toxic, iron-binding copolymer, as a potent (<uM MIC), broad-spectrum, antimicrobial agent active against bacterial and fungal infections, including drug resistant organisms. DIBI augments a natural iron sequestration mechanism, hypoferremia, that starves infections for essential iron. DIBI is also effective against sepsis, inflammatory disorders, and cancer. This water-soluble polymer is ideal for many different routes of administration and has been characterized in 22 published studies. It is non-toxic in animal studies, and because of its unique mechanism of action, it is immune to the development of microbial resistance and inhibits the development of resistance to co-administered antibiotics with which it is synergistic. We are looking to expand the preclinical package for a range of indications, including synergy studies, completion of the toxicology assessment, cGMP DS/DP manufacture and first in human clinical studies.

Andrew Heaton

• Organisation: Fe Pharmaceuticals
• Position: COO
• E-mail: aheaton@chelationpartners.com
• Phone: +1 6072277996
• Web: fepharm.com